$SOTK

Sono-Tek (SOTK) grants director options at $5.35, vesting in 2027

Sono-Tek (SOTK) granted director Eric Haskell 5,396 options at $5.35, exercisable from 2027 and expiring in 2036. Haskell now holds 40,773 derivative securities directly, according to the company.

Original reporting
Published Aug 24, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SOTK
Neutral
high confidence
Mentioned
$SOTK
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$SOTKNeutralLow
01

Why it matters

The grant adds modest dilution and signals insider alignment with shareholders.

02

Market read

Routine insider transaction with limited trading relevance.

03

What to watch

Potential future equity compensation plans or upcoming board decisions.

Relevance 4/10Novelty 4/10Timing: post‑filing Aug 2026

Background

Form 4 filing discloses a director's option grant.

Company-level read

Ticker impact

$SOTKNeutralHigh confidence
Context

Director Eric Haskell was granted 5,396 Sono‑Tek options at $5.35, exercisable Aug 2027, increasing his holdings to 40,773 options.

Expected impact

Limited short‑term impact; price likely unchanged.

Evidence & confidence

The grant size ($29K) is small relative to market cap and does not materially affect supply.

Market effects

No immediate sector impact; insider option grants are routine in tech manufacturing.

US‑focused; no broader regional effect.

Low global relevance.

Counterpoint

Even small insider grants can hint at upcoming positive developments.

Key entities

  • Eric Haskell

    Recipient of the option grant.

Related articles

$SOTKMed

Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sono-Tek Reports Fiscal Second Quarter and First Half 2027 Results Driven by Strong Medical Sector and Higher Value Production Systems First Half Revenue Increased 6% to $10.9 Million; Gross Margin Expanded to 55%; Operating Income Increased 41%; Medical Market Sales

$SOTKMed

Sono-Tek stock rises on record $3.6M production line order

Sono-Tek Corp (NASDAQ:SOTK) shares rose 3.9% premarket after the company said it received a $3.6 million order for an integrated advanced manufacturing production line for medical diagnostic device coating. Sono-Tek said it is its largest single-line order, placed by an existing customer moving to high-volume manufacturing, with shipment expected in fiscal 2028.

$SOTKMedAI 8/10

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Sono-Tek (Nasdaq: SOTK) reported first-quarter fiscal 2027 results for the quarter ended May 31, 2026. Net sales rose 10% to $5.66 million, gross margin expanded to 57% from 52%, operating income increased 86% to $897,000, and net income rose to $741,000 ($0.05 diluted). Cash was $16.65 million with no debt, and backlog was $7.73 million. The company expects continued 1H growth driven by medical demand and higher-value production systems.

$SOTKMed

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm SONO-TEK CORPORATION REPORTS FIRST QUARTER FISCAL 2027 RESULTS Exhibit 99.1 Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67% Anticipati

$SOTKMedAI 9/10

Sono-Tek Corporation Q4 2026 Earnings Call Summary

Sono-Tek Corporation reported Q4 2026 results driven by a shift to higher-ASP, turnkey production systems. The company said medical demand rose 54% year over year, while clean energy orders fell 19% amid government policy changes. Gross margin increased to 51% and operating income rose 81%. Management projected growth and profitability in fiscal 2027 H1, with flat-to-modestly higher full-year revenue amid clean-energy uncertainty. Cash was $14.8 million with no debt.